Conclusion: These findings highlight the potential of GLP-1 analogues in the treatment of Alzheimers disease
Moving forward, Felson wrote, "it will be important to obtain data on whether semaglutide is similarly effective in persons with osteoarthritis without obesity, as well as better data on whether GLP-1 receptor agonists prevent progressive structural deterioration of the joint in osteoarthritis." This double-blind STEP-9 study was conducted at 61 sites across 11 countries starting in October 2021
GLP-1 drugs slow gastric emptying, which means food and supplements stay in the stomach longer
Facial/body flushing when first injected Injection site irritation and/or rash Joint and/or muscle pain Fatigue Pain and swelling after repeated shots to the same injection site- (rotate injection site ) In rare cases, some patients have experienced mild hypertension Water retention Warnings and precautions: CJC1295 and Ipamoralin peptides are banned by WADA (world anti-doping agency) for uses in sports CJC1295 may be mitogenic, if patient is prone to cancer and/or have cancer, use with caution CJC1295 may mask symptoms of hypothyroidism, make sure to test thyroid hormone levels (Free and Total T3, T4, TSH and thyroid antibodies) CJC1295 can cause Congestive Heart Failure, Do Not Use if you have a history of cardiac complications CJC1295 is a growth hormone releasing hormone (GHRH) analog= growth hormone mimetic
Available in Australia: Yes Notes: Use should always be guided by blood levels
J.IurilliG.OlceseU.RacineV.et al
